



International Alliance for  
Biological Standardization



## The Role of Real-World Evidence for Regulatory and Public Health Decision Making for Accelerated Vaccine Deployment

September 19-20, 2023  
Park Inn Hotel, Leuven, Belgium



### **Phil Bryan PhD**

SERM Head, Executive Director  
Viral and DTP combination Vaccines  
GlaxoSmithKline

E-mail: [philip.t.bryan@gsk.com](mailto:philip.t.bryan@gsk.com)

Phil is a Safety Evaluation & Risk Management Head (SERM) at GSK, overseeing a Group responsible for the safety of a range of vaccines including RSV, Zoster, Malaria and DTP combination vaccines. In the 20 years before joining industry, Phil was the UK MHRA lead on vaccine safety and worked closely with UK health authorities to develop and implement risk management strategies for the UK immunisation programme. He led the MHRA's COVID vaccine PV strategy, and was a member of the WHO GACVS COVID subcommittee. As an EU expert in vaccine safety, Phil co-authored several EMA guidelines on vaccines and biologicals pharmacovigilance, and has been actively involved in multistakeholder vaccine safety initiatives.

